On December 19, 2025, BioMarin Pharmaceutical Inc. entered into an agreement to acquire Amicus Therapeutics, paying $14.50 per share in cash, with the merger expected to close in the second quarter of 2026.
AI Assistant
BIOMARIN PHARMACEUTICAL INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.